FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)Active
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma Active Biotech.
The correction refers to the administrative costs for the period January - December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK 15
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular